|
1
|
Gonzalez-Diego P, Lopez-Abente G, Pollan M
and Ruiz M: Time trends in ovarian cancer mortality in Europe
(1955–1993): Effect of age, birth cohort and period of death. Eur J
Cancer. 36:1816–1824. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grabowski JP and Sehouli J: Current
management of ovarian cancer. Minerva Med. 106:151–156.
2015.PubMed/NCBI
|
|
3
|
Aletti GD, Gallenberg MM, Cliby WA, Jatoi
A and Hartmann LC: Current management strategies for ovarian
cancer. Mayo Clin Proc. 82:751–770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Salzberg M, Thurlimann B, Bonnefois H,
Fink D, Rochlitz C, von Moos R and Senn H: Current concepts of
treatment strategies in advanced or recurrent ovarian cancer.
Oncology. 68:293–298. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peluso JJ, Gawkowska A, Liu X, Shioda T
and Pru JK: Progesterone receptor membrane component-1 regulates
the development and Cisplatin sensitivity of human ovarian tumors
in athymic nude mice. Endocrinology. 150:4846–4854. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peluso JJ, Liu X, Saunders MM, Claffey KP
and Phoenix K: Regulation of ovarian cancer cell viability and
sensitivity to cisplatin by progesterone receptor membrane
component-1. J Clin Endocrinol Metab. 93:1592–1599. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zheng Q, Li Y, Zhang D, Cui X, Dai K, Yang
Y, Liu S, Tan J and Yan Q: ANP promotes proliferation and inhibits
apoptosis of ovarian granulosa cells by NPRA/PGRMC1/EGFR complex
and improves ovary functions of PCOS rats. Cell Death Dis.
8:e31452017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ryu CS, Klein K and Zanger UM: Membrane
associated progesterone receptors: Promiscuous proteins with
pleiotropic functions-focus on interactions with cytochromes P450.
Front Pharmacol. 8:1592017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mir SU, Schwarze SR, Jin L, Zhang J,
Friend W, Miriyala S, St Clair D and Craven RJ: Progesterone
receptor membrane component 1/Sigma-2 receptor associates with
MAP1LC3B and promotes autophagy. Autophagy. 9:1566–1578. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahmed IS, Rohe HJ, Twist KE, Mattingly MN
and Craven RJ: Progesterone receptor membrane component 1 (Pgrmc1):
A heme-1 domain protein that promotes tumorigenesis and is
inhibited by a small molecule. J Pharmacol Exp Ther. 333:564–573.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Middleton E Jr, Kandaswami C and
Theoharides TC: The effects of plant flavonoids on mammalian cells:
Implications for inflammation, heart disease, and cancer. Pharmacol
Rev. 52:673–751. 2000.PubMed/NCBI
|
|
12
|
Ji S, Li R, Wang Q, Miao WJ, Li ZW, Si LL,
Qiao X, Yu SW, Zhou DM and Ye M: Anti-H1N1 virus, cytotoxic and
Nrf2 activation activities of chemical constituents from
Scutellaria baicalensis. J Ethnopharmacol. 176:475–484. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu L, Zhao L, Wang H, Wang Y, Pan D, Yao
J, Li Z, Wu G and Guo Q: Oroxylin A reverses
P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by
G2/M arrest. Toxicol Lett. 219:107–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Yang L and Lee TJ: Oroxylin A
inhibition of lipopolysaccharide-induced iNOS and COX-2 gene
expression via suppression of nuclear factor-kappaB activation.
Biochem Pharmacol. 59:1445–1457. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu M, Lu N, Sun Z, Zhang H, Dai Q, Wei L,
Li Z, You Q and Guo Q: Activation of the unfolded protein response
contributed to the selective cytotoxicity of oroxylin A in human
hepatocellular carcinoma HepG2 cells. Toxicol Lett. 212:113–125.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu ZF, Sun XK, Chen G, Han C, Wang F and
Zhang YD: Oroxyloside inhibits human glioma progression by
suppressing proliferation, metastasis and inducing apoptosis
related pathways. Biomed Pharmacother. 97:1564–1574. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun X, Chang X, Wang Y, Xu B and Cao X:
Oroxylin a suppresses the cell proliferation, migration, and EMT
via NF-κB signaling pathway in human breast cancer cells. Biomed
Res Int. 2019:92417692019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei M, Ma R, Huang S, Liao Y, Ding Y, Li
Z, Guo Q, Tan R, Zhang L and Zhao L: Oroxylin A increases the
sensitivity of temozolomide on glioma cells by hypoxia-inducible
factor 1α/hedgehog pathway under hypoxia. J Cell Physiol.
234:17392–17404. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wei L, Yao Y, Zhao K, Huang Y, Zhou Y,
Zhao L, Guo Q and Lu N: Oroxylin A inhibits invasion and migration
through suppressing ERK/GSK-3β signaling in snail-expressing
non-small-cell lung cancer cells. Mol Carcinog. 55:2121–2134. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hui H, Chen Y, Yang H, Zhao K, Wang Q,
Zhao L, Wang X, Li Z, Lu N and Guo Q: Oroxylin A has therapeutic
potential in acute myelogenous leukemia by dual effects targeting
PPARγ and RXRα. Int J Cancer. 134:1195–1206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Evans RM: The steroid and thyroid hormone
receptor superfamily. Science. 240:889–895. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schoonjans K, Martin G, Staels B and
Auwerx J: Peroxisome proliferator-activated receptors, orphans with
ligands and functions. Curr Opin Lipidol. 8:159–166. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alarcon de la Lastra C, Sanchez-Fidalgo S,
Villegas I and Motilva V: New pharmacological perspectives and
therapeutic potential of PPAR-gamma agonists. Curr Pharm Des.
10:3505–3524. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kubota T, Koshizuka K, Williamson EA, Asou
H, Said JW, Holden S, Miyoshi I and Koeffler HP: Ligand for
peroxisome proliferator-activated receptor gamma (troglitazone) has
potent antitumor effect against human prostate cancer both in vitro
and in vivo. Cancer Res. 58:3344–3352. 1998.PubMed/NCBI
|
|
25
|
Luo S, Wang J, Ma Y, Yao Z and Pan H:
PPARγ inhibits ovarian cancer cells proliferation through
upregulation of miR-125b. Biochem Biophys Res Commun. 462:85–90.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim S, Lee JJ and Heo DS: PPARγ ligands
induce growth inhibition and apoptosis through p63 and p73 in human
ovarian cancer cells. Biochem Biophys Res Commun. 406:389–395.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang X, Sun Y, Zhao Y, Ding Y, Zhang X,
Kong L, Li Z, Guo Q and Zhao L: Oroxyloside prevents dextran
sulfate sodium-induced experimental colitis in mice by inhibiting
NF-KB pathway through PPARγ activation. Biochem Pharmacol.
106:70–81. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu X, Chen Y, Zhu W, Ji M, Xu J, Guo Y,
Gao F, Gu W, Yang X and Zhang C: Oroxylin A inhibits Kaposi's
sarcoma-associated herpes virus (KSHV) vIL-6-mediated lymphatic
reprogramming of vascular endothelial cells through modulating
PPARγ/Prox1 axis. J Med Virol. 91:463–472. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu X, Ji M, Han Y, Guo Y, Zhu W, Gao F,
Yang X and Zhang C: PGRMC1-dependent autophagy by hyperoside
induces apoptosis and sensitizes ovarian cancer cells to cisplatin
treatment. Int J Oncol. 50:835–846. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu X, Han Y, Fang Z, Wu W, Ji M, Teng F,
Zhu W, Yang X, Jia X and Zhang C: Progesterone protects ovarian
cancer cells from cisplatin-induced inhibitory effects through
progesterone receptor membrane component 1/2 as well as AKT
signaling. Oncol Rep. 30:2488–2494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wei L, Dai Y, Zhou Y, He Z, Yao J, Zhao L,
Guo Q and Yang L: Oroxylin A activates PKM1/HNF4 alpha to induce
hepatoma differentiation and block cancer progression. Cell Death
Dis. 8:e29442017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ni T, He Z, Dai Y, Yao J, Guo Q and Wei L:
Oroxylin A suppresses the development and growth of colorectal
cancer through reprogram of HIF1α-modulated fatty acid metabolism.
Cell Death Dis. 8:e28652017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singh J and Kakkar P: Oroxylin A, a
constituent of Oroxylum indicum inhibits adipogenesis and induces
apoptosis in 3T3-L1 cells. Phytomedicine. 21:1733–1741. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qiao C, Wei L, Dai Q, Zhou Y, Yin Q, Li Z,
Xiao Y, Guo Q and Lu N: UCP2-related mitochondrial pathway
participates in oroxylin A-induced apoptosis in human colon cancer
cells. J Cell Physiol. 230:1054–1063. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nakahata N, Kutsuwa M, Kyo R, Kubo M,
Hayashi K and Ohizumi Y: Analysis of inhibitory effects of
scutellariae radix and baicalein on prostaglandin E2 production in
rat C6 glioma cells. Am J Chin Med. 26:311–323. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu Y, Yang Y, You QD, Liu W, Gu HY, Zhao
L, Zhang K, Wang W, Wang XT and Guo QL: Oroxylin A induced
apoptosis of human hepatocellular carcinoma cell line HepG2 was
involved in its antitumor activity. Biochem Biophys Res Commun.
351:521–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang Y, Hu Y, Gu HY, Lu N, Liu W, Qi Q,
Zhao L, Wang XT, You QD and Guo QL: Oroxylin A induces G2/M phase
cell-cycle arrest via inhibiting Cdk7-mediated expression of
Cdc2/p34 in human gastric carcinoma BGC-823 cells. J Pharm
Pharmacol. 60:1459–1463. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun Y, Lu N, Ling Y, Gao Y, Chen Y, Wang
L, Hu R, Qi Q, Liu W, Yang Y, et al: Oroxylin A suppresses invasion
through down-regulating the expression of matrix
metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Eur
J Pharmacol. 603:22–28. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li HN, Nie FF, Liu W, Dai QS, Lu N, Qi Q,
Li ZY, You QD and Guo QL: Apoptosis induction of oroxylin A in
human cervical cancer HeLa cell line in vitro and in vivo.
Toxicology. 257:80–85. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hu R, Chen N, Yao J, Zhao Q, Zhang F, Li
ZY, You QD and Guo QL: The role of Nrf2 and apoptotic signaling
pathways in oroxylin A-mediated responses in HCT-116 colorectal
adenocarcinoma cells and xenograft tumors. Anticancer Drugs.
23:651–658. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu Y, Sun Y, Zhu J, Yu L, Jiang X, Zhang
J, Dong X, Ma B and Zhang Q: Oridonin exerts anticancer effect on
osteosarcoma by activating PPARγ and inhibiting Nrf2 pathway. Cell
Death Dis. 9:152018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheng WY, Huynh H, Chen P, Pena-Llopis S
and Wan Y: Macrophage PPARγ inhibits Gpr132 to mediate the
anti-tumor effects of rosiglitazone. Elife. 5:e185012016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee NJ, Oh JH, Ban JO, Shim JH, Lee HP,
Jung JK, Ahn BW, Yoon DY, Han SB, Ham YW and Hong JT:
4-O-methylhonokiol, a PPARγ agonist, inhibits prostate tumour
growth: p21-mediated suppression of NF-KB activity. Br J Pharmacol.
168:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim JY, Kim SY, Choi HS, Kim MK, Lee HM,
Jang YJ and Ryu CJ: Progesterone receptor membrane component 1
suppresses the p53 and Wnt/β-catenin pathways to promote human
pluripotent stem cell self-renewal. Sci Rep. 8:30482018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vallée A, Vallee JN, Guillevin R and
Lecarpentier Y: Interactions between the canonical WNT/Beta-catenin
pathway and PPAR gamma on neuroinflammation, demyelination, and
remyelination in multiple sclerosis. Cell Mol Neurobiol.
38:783–795. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mir SU, Jin L and Craven RJ: Neutrophil
gelatinase-associated lipocalin (NGAL) expression is dependent on
the tumor-associated sigma-2 receptor S2RPgrmc1. J Biol Chem.
287:14494–14501. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu L, Liu X, Bai Y, Tang N, Li J, Zhang
Y, Wu J, Wang X and Wei J: Neuregulin-1β modulates myogenesis in
septic mouse serum-treated C2C12 myotubes in vitro through
PPARγ/NF-KB signaling. Mol Biol Rep. 45:1611–1619. 2018. View Article : Google Scholar : PubMed/NCBI
|
